Browsing Tag
NASDAQ
801 posts
Bending Spoons agrees $1.28bn all-cash Airtable deal in first post-IPO acquisition
Bending Spoons pays $1.285 billion for Airtable in its first post-IPO deal, testing whether public capital can sustain a rollup once fuelled by debt and PE.
Braveheart Bio IPO targets $1.2bn valuation as HCM drug race heats up
Braveheart Bio is seeking up to $318.8 million in its Nasdaq IPO, but investors must decide whether its cardiac myosin inhibitor can compete in an increasingly crowded hypertrophic cardiomyopathy market.
Lantern Pharma just separated its AI platform, but will Open Medicine AI unlock real shareholder value?
Lantern Pharma has established Open Medicine AI as a separate company to commercialize and expand its multi-agent AI co-scientist platform, moving a previously planned separation into an active corporate structure. The decision could give the artificial intelligence business greater strategic focus and access to specialized funding, but ownership, intellectual property, customer revenue and future listing arrangements will determine whether the move creates measurable value for Lantern Pharma shareholders.
Amgen data breach: Patient records exposed via third-party cloud storage
Amgen said patient health data was exfiltrated via third-party cloud storage in an incident deemed material days before its August 4 Q2 earnings release.
OceanFirst (NASDAQ: OCFC) absorbs $42.8m merger costs, core earnings jump on Flushing deal
OceanFirst's Q2 loss stems from $42.8M Flushing merger costs; core EPS of $0.43 beat and NIM expanded to 3.05%. Q3 integration will test the deal thesis.
IES Holdings (NASDAQ: IESC) stock surges after Q3 earnings and two-for-one split
IES Holdings surged after Q3 earnings and a stock split, but backlog conversion and residential weakness will decide whether NASDAQ can hold momentum.
Cavco Industries (CVCO) Q1 FY27: Backlog jumps 53% to $298m as factory-built margin slips and EPS misses
Cavco Q1 FY27 backlog jumped 53% to $298M ahead of the ROAD to Housing Act rollout, but factory margin fell to 20.8% and EPS dropped to $5.43.
Space-Eyes lines up $638m Nasdaq debut via McKinley SPAC as Eric Trump joins as strategic adviser
Space-Eyes agrees $638M Nasdaq listing via McKinley SPAC with Eric Trump advising, on $1M revenue and a $35M pipeline. Can contract conversion close the gap?
IES Holdings (NASDAQ: IESC) smashes Q3 estimates: Revenue up 40%, adjusted EPS jumps to $6.70
IES Holdings surged 26% after Q3 revenue jumped 40% to $1.24B and backlog hit $4.5B, up 91% since September, on data center demand and a 2-for-1 split.
Why argenx is buying Forte Biosciences before FB102 enters its bigger proof stage
argenx agrees to buy Forte Biosciences for $2.2 billion. Read how FB102 could reduce Vyvgart concentration risk and reshape ARGX’s autoimmune strategy.